The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
When your investment case breaks down, why not just do the decent thing?
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.